Share This Page
Drug Price Trends for ROBAFEN CF LIQUID
✉ Email this page to a colleague
Average Pharmacy Cost for ROBAFEN CF LIQUID
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ROBAFEN CF LIQUID | 00904-6537-20 | 0.02076 | ML | 2026-03-18 |
| ROBAFEN CF LIQUID | 00904-6537-20 | 0.02026 | ML | 2026-02-18 |
| ROBAFEN CF LIQUID | 00904-6537-20 | 0.01982 | ML | 2026-01-21 |
| ROBAFEN CF LIQUID | 00904-6537-20 | 0.01953 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for ROBAFEN CF LIQUID
What is ROBAFEN CF LIQUID?
ROBAFEN CF LIQUID is an over-the-counter medication combining dextromethorphan, guaifenesin, and phenylephrine. It is used to treat cough, chest congestion, and related symptoms associated with colds and respiratory infections. The formulation is designed to be administered orally in liquid form, typically marketed toward pediatric and adult populations.
Market Overview
Market Size and Sales Trends
The global cough and cold remedy market was valued at approximately $8.2 billion in 2022. It has grown at a compound annual growth rate (CAGR) of 3.4% since 2017. The key drivers include increased consumer awareness, rising prevalence of respiratory illnesses, and higher demand for combination products.
Within this market, liquid formulations account for roughly 28% of sales, valued at approximately $2.3 billion in 2022. The liquid segment remains favored in pediatric care and for consumers preferring easy-to-dose options.
Geographic Distribution
- North America: 45% of sales, driven by high OTC drug consumption and established brand presence.
- Europe: 25%, with growth influenced by regulatory tightening favoring OTC products.
- Asia-Pacific: 20%, expanding due to increasing healthcare infrastructure and consumer access.
- Rest of the world: 10%.
Competitive Landscape
Major players include Johnson & Johnson, Reckitt Benckiser, Pfizer, and GlaxoSmithKline. These companies hold approximately 65% of market share combined.
Key product competitors to ROBAFEN CF LIQUID include:
- Mucinex Chest Congestion Expert
- Robitussin Chest Congestion
- Children’s Dimetapp Cold & Cough
These products vary from single-agent to combination formulations and differ in dosage, packaging, and marketing.
Regulatory Environment
In the U.S., the product is regulated by the Food and Drug Administration (FDA) as an OTC monograph drug. It complies with the OTC Monograph for Combination Cold, Cough, and Allergy Products.
In the European Union, it falls under medicinal product regulations, requiring registration in each member state.
Regulatory agencies across Asia-Pacific are adopting similar guidelines, with some countries requiring local clinical data for OTC approval.
Price Analysis
Current Pricing
Average retail prices for a 4 fl oz (120 ml) bottle of ROBAFEN CF LIQUID range from $8 to $12 in the U.S., depending on the retailer and packaging size.
- Estimated manufacturing cost: $1.20 per bottle, considering raw materials, packaging, labor, and logistics.
- Wholesale price: $6–$8.
- Retail markup: 30–50%.
In Europe, retail prices are comparable, with local market adjustments. In Asia-Pacific, prices range from $5 to $9, influenced by import tariffs and local regulations.
Price Sensitivity
Price elasticity for OTC cold remedies is moderate. Consumers respond to promotions, brand recognition, and perceived efficacy. Price increases above 10% usually lead to reduced sales volume unless justified by proven efficacy or brand loyalty, per industry reports.
Future Pricing Trends
Projected price adjustments follow:
- Raw material costs: Increasing at an annual rate of 1.5%, driven by supply chain disruptions.
- Regulatory costs: Rising due to stricter compliance in various markets, increasing average compliance costs by 2–3% annually.
- Competitive dynamics: Price competition may intensify, especially with lower-cost generics entering the market.
Price Projections
By 2025, prices for similar products might increase by 4–6% domestically, reflecting inflation and production cost escalations. The retail price for a 4 fl oz bottle could reach approximately $10–$13 in the U.S. market.
Key Factors Influencing Price and Market Dynamics
- Regulatory changes, especially potential restrictions on combination products containing phenylephrine.
- Market penetration by generic versions—most OTC formulations are facing increased generic competition.
- Consumer health trends favoring natural or minimal-ingredient remedies may impact sales.
- Expansion in emerging markets offers potential for volume growth but may pressure prices downward due to local pricing policies.
Summary
| Aspect | Data |
|---|---|
| Market size (2022) | $8.2 billion (global cough/cold remedy market) |
| Liquid formulation share | 28% (~$2.3 billion, 2022) |
| North America share | 45% |
| Leading competitors | Johnson & Johnson, Reckitt, Pfizer, GSK |
| Retail price (U.S., 2022) | $8–$12 per 4 fl oz |
| Cost of goods | Approx. $1.20 per bottle |
| Projected retail price (2025) | $10–$13 |
Key Takeaways
- The global OTC cough and cold market remains sizeable, with liquid formulations maintaining a significant share.
- Price points are constrained by consumer sensitivity and competitive pressures.
- Generics and regulatory changes influence both pricing and market share.
- Future pricing trends anticipate moderate increases aligned with inflation and cost pressures.
- Market growth depends on regulatory developments, geographic expansion, and shifting consumer preferences.
FAQs
1. How does the regulatory environment affect pricing for OTC cold remedies? Regulatory requirements increase compliance costs, which can push retail prices upward. Stricter regulations on ingredient safety or marketing can also impact market availability and pricing strategies.
2. What impact do generic competitors have on ROBAFEN CF LIQUID’s market share? Generics typically reduce prices and erode margins for branded products, increasing price competition and leading to potential market share declines for the original formulation.
3. Are there regional pricing differences for ROBAFEN CF LIQUID? Yes. Pricing varies due to local regulations, import tariffs, distribution channels, and consumer purchasing power. Prices tend to be higher in North America and Europe than in Asia-Pacific.
4. How might consumer trends influence future pricing? Growth of preference for natural or minimal-ingredient products could decrease demand for traditional combination remedies, potentially reducing prices or leading to product reformulation.
5. What are the key drivers of market growth for cough and cold remedies? Increasing respiratory disease prevalence, improved healthcare access, and high consumer OTC medication usage support market growth globally.
References
[1] Statista. (2023). OTC cold remedies market size and trends.
[2] MarketsandMarkets. (2022). Over-the-counter (OTC) drug market report.
[3] FDA. (2022). Over-the-counter monograph regulation updates.
[4] EuroMonitor. (2021). Pharmaceutical OTC market analysis.
[5] IBISWorld. (2022). Cough, Cold, and Flu Medicine Industry.
More… ↓
